FDA warns of compounded drug recall by Texas firm

(AP)—The Food and Drug Administration is warning doctors not to use compounded drugs from a Texas specialty pharmacy due to risks of contamination.

The agency says FDA inspectors recently uncovered unsanitary conditions at Unique Pharmaceuticals' plant in Temple, Texas. The inspections revealed production problems in several lots of drugs that were supposed to be sterile.

The company is now recalling all non-expired sterile products distributed across the U.S., including a fluid used to clear mucus from the airways of patients with respiratory conditions.

The FDA said in a statement it is not aware of any illnesses linked to the products.

Unique Pharmaceuticals is a compounding pharmacy, which means it produces customized medications to fill specifications made by doctors.

Compounding pharmacy operations have been repeatedly linked to contamination problems for decades.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Indianapolis pharmacy recalls compounded drugs

Apr 23, 2013

(AP)—A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.

Fla. compounding pharmacy recalls sterile drugs

Apr 21, 2013

A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

FDA: Georgia pharmacy recalling all sterile drugs

Mar 21, 2013

(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.

Recommended for you

Supercomputers link proteins to drug side effects

5 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

12 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments